Propofol in subanesthetic doses terminates status epilepticus in a rodent model.
Status epilepticus is commonly refractory to first-line therapy, and thus better treatments are needed. We have investigated an experimental model of drug-resistant self-sustaining status epilepticus (SSSE) induced by 2 hours of perforant path stimulation. Propofol in subanesthetic doses administered shortly after the end of stimulation and also after a further 3 hours of SSSE terminated the SSSE without recurrence. This finding calls for a trial of propofol in refractory status epilepticus and also raises the possibility of using it as first-line therapy.
Holtkamp
M
M
Klinik fuer Neurologie, Charité, Humboldt-Universitaet, Berlin, Germany.
Tong
X
X
Walker
M C
MC
D000818:Animals; D004195:Disease Models, Animal; D004558:Electric Stimulation; D015742:Propofol / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013226:Status Epilepticus / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D015742:Propofol